Apogee makes long-interval dosing case in atopic dermatitis, Valneva falls on Lyme disease data, and more

Shares of Apogee rose 20% Monday after the company reported what could be a best-in-class 52-week durability profile in atopic dermatitis, with symptom control that appears competitive with other injectables and a less frequent dosing schedule of once every 3 or 6 months.

In 52-week follow-up data from the 16-week APEX Part A readout, Apogee Therapeutics Inc. (NASDAQ:APGE) said 75% and 85% of week-16 responders on the  Eczema Area and Severity Index of ≥ 75 (EASI 75) endpoint maintained that response through one year on every-3- and every-6-month dosing, respectively. Corresponding maintenance rates those who attained a validated Investigator’s Global Assessment (vIGA) of 0 or 1 — indicating clear or almost clear skin — were 86% and 78%. The company said efficacy deepened across lesion and itch endpoints in the full zumilokibart-treated population...